UnitedHealth (UNH) Shows Steady Turnaround Progress in Q3 2026 Earnings
Key Takeaways
- UnitedHealth reported third quarter 2026 revenue of $112.7 billion, slightly lower than a year ago but ahead of the $111.31 billion consensus estimate.
- Adjusted earnings per share (EPS) came in at $4.69, beating the roughly $4.14 Wall Street estimate and rising sharply from $2.92 a year earlier.
- The medical care ratio (MCR), the share of premiums spent on patient care, improved to 88.4% from 89.9%, reflecting stronger cost controls.
- Full-year 2026 adjusted EPS guidance was raised to at least $20.50, the third upward revision of the year.
- Shares rose in early trading as the results reinforced progress in the company's multi-year operational turnaround.
Why These Results Matter
UnitedHealth Group is the largest U.S. health insurer and a bellwether for the broader managed care sector. Its quarterly results carry outsized weight because they signal trends in medical costs, Medicare Advantage profitability, and pharmacy benefit management that ripple across peers. This report matters especially after a difficult 2025, when elevated medical expenses and weakness in the Optum Health business sent shares down sharply. Investors have since watched for evidence that pricing discipline, benefit design changes, and portfolio exits are restoring margins. The third quarter offered a key test of whether that recovery is durable heading into 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Showed
UnitedHealth posted third quarter 2026 revenue of $112.7 billion, down 0.4% year over year but above the $111.31 billion consensus. Adjusted EPS was $4.69, surpassing the roughly $4.14 analysts expected and up from $2.92 a year earlier. On a generally accepted accounting principles (GAAP) basis, diluted EPS was $4.56, compared with $2.59 in the prior-year quarter, while net income rose to about $4.11 billion from $2.35 billion.
The closely watched MCR improved to 88.4% from 89.9%, better than the roughly 89.7% forecast. Operating margin widened to 5.8% from 3.8%. The insurance arm, UnitedHealthcare, generated revenue of $86.3 billion and served 48.3 million people, while Optum revenue declined about 3% to roughly $66.9 billion, largely reflecting a deliberate pullback in lower-margin value-based care markets.
Management raised full-year 2026 adjusted EPS guidance to at least $20.50, up from a prior range of $19.50 to $20.00.
How the Market Responded
Shares rose in early trading following the release, advancing roughly 2% to 4% in premarket activity and pulling peers such as Humana and CVS Health higher. The market read the beat on both EPS and revenue, combined with a better-than-expected MCR, as confirmation that cost management efforts are working. Analysts described the quarter as another strong step in the turnaround, highlighting upside on medical costs and improved performance at Optum Health. Still, some caution persisted: executives noted that commercial medical trends remain elevated and that Medicaid margins continue to face pressure, tempering optimism about the pace of further improvement.
What to Watch Next
Investors will now focus on whether UnitedHealth can sustain its margin recovery through year-end and into 2027. The company's raised full-year guidance of at least $20.50 in adjusted EPS sets a higher bar, but management flagged expected investments in technology, artificial intelligence, and workflow improvements during the fourth quarter.
Medical cost trends remain the central swing factor. While the MCR improved year over year, executives cautioned that utilization is still elevated against historical norms, with specialty pharmaceuticals and arbitration awards tied to the No Surprises Act adding pressure in commercial plans.
Membership dynamics also warrant attention. Medicare Advantage enrollment has contracted as the company retools its portfolio for profitability, and Medicaid rolls continue to shrink amid ongoing eligibility redeterminations. Whether growth returns in 2027 will depend on positioning during the annual enrollment period.
Finally, watch balance sheet priorities, including progress toward a roughly 40% debt-to-capital ratio and continued share repurchases and dividends, which signal how confidently management views its cash generation.
Integrating AI Tools into My Research
When analyzing healthcare names like this, I often turn to Tickeron’s AI Screener to quickly filter for comparable stocks based on technical patterns, fundamentals, and AI-driven signals. It helps surface sector trends and potential opportunities without spending hours on manual screening, which keeps my process more efficient while I focus on the bigger picture.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UNH's Indicator enters downward trend
The Aroon Indicator for UNH entered a downward trend on October 12, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 123 similar instances where the Aroon Indicator formed such a pattern. In 83 of the 123 cases the stock moved lower. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 63 cases where UNH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UNH's RSI Indicator exited the oversold zone, 25 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on UNH as a result. In 46 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for UNH just turned positive on October 05, 2026. Looking at past instances where UNH's MACD turned positive, the stock continued to rise in 26 of 46 cases over the following month. The odds of a continued upward trend are 57%.
Following a +3.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.445) is normal, around the industry mean (3.247). P/E Ratio (24.282) is within average values for comparable stocks, (139.958). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of hospital and medical service plans
Industry ManagedHealthCare
Advertisement